Jet Identification with Zest

We present a new observable zest and demonstrate its potential to differentiate between jets originated by gluons, top quark and vector bosons. Zest has salient properties such as boost invariance, stability against global color flow of partons and inclusion or exclusion of a few soft particles to the jet. For a gluon jet, zest distribution is also insensitive to the jet mass. We show that when zest is used in conjunction with other observables, it can yield high gluon rejection while retaining high signal sample.Comment: 3 pages, 5 figures, XXII DAE-BRNS Symposium Proceeding

One-loop Angularity Distributions with Recoil using Soft-Collinear Effective Theory

Angularities are event shapes whose sensitivity to the splitting angle of a collinear emission is controlled by a continuous parameter $b$, with $-1 < b < \infty$. When measured with respect to the thrust axis, this class of QCD observables includes thrust ($b=1$) and jet broadening ($b=0$), the former being insensitive to the recoil of soft against collinear radiation, while the latter being maximally sensitive to it. Presently available analytic results for angularity distributions with $b \neq 0$ can be applied only close to the thrust limit since recoil effects have so far been neglected. As a first step to establish a comprehensive theoretical framework based on Soft-Collinear Effective Theory valid for all recoil-sensitive angularities, we compute for the first time angularity distributions at one-loop order in $\alpha_s$ for all values of $b$ taking into account recoil effects. In the differential cross section, these amount to novel sub-leading singular contributions and/or power corrections, where the former are characterized by fractional powers of the angularity and contribute appreciably close to the peak region, also for $b \gtrsim 0.5$. Our calculations are checked against various limits known in the literature and agree with the numerical output of the Event2 generator.Comment: 45 pages, 7 figures, v2: improved discussion, version accepted for publication in JHE

A twisted tale of the transverse-mass tail

We propose a tantalizing possibility that misinterpretation of the reconstructed missing momentum may have yielded the observed discrepancies among measurements of the $W$-mass in different collider experiments. We introduce a proof-of-principle scenario characterized by a new physics particle, which can be produced associated with the $W$-boson in hadron collisions and contributes to the net missing momentum observed in a detector. We show that these exotic events pass the selection criteria imposed by various collaborations at reasonably high rates. Consequently, in the presence of even a handful of these events, a fit based on the ansatz that the missing momentum is primarily due to neutrinos (as it happens in the Standard Model), yields a $W$-boson mass that differs from its true value. Moreover, the best fit mass depends on the nature of the collider and the center-of-mass energy of collisions. We construct a barebones model that demonstrates this possibility quantitatively while satisfying current constraints. Interestingly, we find that the nature of the new physics particle and its interactions appear as a variation of the physics of Axion-like particles after a field redefinition.Comment: 24 pages, 7 figures, a new appendix added, version published in JHE

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Angularity Distributions at One Loop with Recoil

Angularities are a general class of event shapes which depend on a continuous parameter $b>-1$ that interpolates between recoil-insensitive observables like thrust and observables that are maximally sensitive to recoil effects like jet broadening. We present the first analytic calculations for angularity singular cross section at one-loop order taking into account the recoil effects, irrespective of the exponent b, within the Soft Collinear Effective Theory (SCET) framework. In the differential cross section, these recoil effects contribute to new terms which can have important consequences on resummation of the large logarithms. Our one-loop fixed-order results are checked against numerical results from Event2 generator